Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease.

Alzheimer's disease is the commonest dementia. One major characteristic of its pathology is accumulation of amyloid-beta (Abeta) as insoluble deposits in brain parenchyma and in blood vessel walls [cerebral amyloid angiopathy (CAA)]. The distribution of Abeta deposits in the basement membranes of cerebral capillaries and arteries corresponds to the perivascular drainage pathways by which interstitial fluid (ISF) and solutes are eliminated from the brain--effectively the lymphatic drainage of the brain. Theoretical models suggest that vessel pulsations supply the motive force for perivascular drainage of ISF and solutes. As arteries stiffen with age, the amplitude of pulsations is reduced and insoluble Abeta is deposited in ISF drainage pathways as CAA, thus, further impeding the drainage of soluble Abeta. Failure of perivascular drainage of Abeta and deposition of Abeta in the walls of arteries has two major consequences: (i) intracerebral hemorrhage associated with rupture of Abeta-laden arteries in CAA; and (ii) Alzheimer's disease in which failure of elimination of ISF, Abeta and other soluble metabolites from the brain alters homeostasis and the neuronal environment resulting in cognitive decline and dementia. Therapeutic strategies that improve elimination of Abeta and other soluble metabolites from the brain may prevent cognitive decline in Alzheimer's disease.

[1]  R O Weller,et al.  Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries: significance for cerebral amyloid angiopathy and neuroimmunology , 2008, Neuropathology and applied neurobiology.

[2]  N. Tomura,et al.  Reduced Perfusion Reserve in Leukoaraiosis Demonstrated Using Acetazolamide Challenge 123I-IMP SPECT , 2007, Journal of computer assisted tomography.

[3]  Phillip B. Jones,et al.  Age-dependent cerebrovascular dysfunction in a transgenic mouse model of cerebral amyloid angiopathy. , 2007, Brain : a journal of neurology.

[4]  A. Goate,et al.  Clearance of amyloid-β by circulating lipoprotein receptors , 2007, Nature Medicine.

[5]  D. Holtzman,et al.  Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. , 2007, The American journal of pathology.

[6]  K. Jellinger,et al.  Topographical distribution of cerebral amyloid angiopathy and its effect on cognitive decline are influenced by Alzheimer disease pathology , 2007, Journal of the Neurological Sciences.

[7]  D. Selkoe,et al.  Aβ Oligomers – a decade of discovery , 2007, Journal of neurochemistry.

[8]  D. Holtzman,et al.  Transport Pathways for Clearance of Human Alzheimer's Amyloid β-Peptide and Apolipoproteins E and J in the Mouse Central Nervous System , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[9]  M. Frosch,et al.  Course of cerebral amyloid angiopathy–related inflammation , 2007, Neurology.

[10]  Rebecca F. Halperin,et al.  A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. , 2007, The Journal of clinical psychiatry.

[11]  E. Reiman.  In this issue: entering the era of high-density genome-wide association studies. , 2007, Journal of Clinical Psychiatry.

[12]  D. Selkoe,et al.  The APP family of proteins: similarities and differences. , 2007, Biochemical Society transactions.

[13]  W. Szarek,et al.  Heparan sulfate as a therapeutic target in amyloidogenesis: prospects and possible complications , 2007, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[14]  T. Révész,et al.  Molecular chaperons, amyloid and preamyloid lesions in the BRI2 gene‐related dementias: a morphological study , 2006, Neuropathology and applied neurobiology.

[15]  S. Love,et al.  Decreased Expression and Activity of Neprilysin in Alzheimer Disease Are Associated With Cerebral Amyloid Angiopathy , 2006, Journal of neuropathology and experimental neurology.

[16]  H. Braak,et al.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry , 2006, Acta Neuropathologica.

[17]  J. Hardy,et al.  Amyloid at the blood vessel wall , 2006, Nature Medicine.

[18]  V. Perry,et al.  Mechanisms to explain the reverse perivascular transport of solutes out of the brain. , 2006, Journal of theoretical biology.

[19]  M. Jaskólski,et al.  The Role of Cystatin C in Cerebral Amyloid Angiopathy and Stroke: Cell Biology and Animal Models , 2006, Brain pathology.

[20]  Mathias Jucker,et al.  Mechanism of Cerebral β‐Amyloid Angiopathy: Murine and Cellular Models , 2006 .

[21]  M. Frosch,et al.  The Cerebral β‐Amyloid Angiopathies: Hereditary and Sporadic , 2006 .

[22]  Steven Mennerick,et al.  Synaptic Activity Regulates Interstitial Fluid Amyloid-β Levels In Vivo , 2005, Neuron.

[23]  A. Fagan,et al.  P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. , 2005, The Journal of clinical investigation.

[24]  Y. Lacasse,et al.  From the authors , 2005, European Respiratory Journal.

[25]  R. Weller,et al.  Cerebral amyloid angiopathy: Both viper and maggot in the brain , 2005, Annals of neurology.

[26]  Eric E. Smith,et al.  Spatial clustering of hemorrhages in probable cerebral amyloid angiopathy , 2005, Annals of neurology.

[27]  K. Hatanpaa.  The Neuropathology of Dementia, 2nd ed , 2005 .

[28]  Brian J Bacskai,et al.  Progression of Cerebral Amyloid Angiopathy in Transgenic Mouse Models of Alzheimer Disease , 2005, Journal of neuropathology and experimental neurology.

[29]  R. Weller.  Microscopic morphology and histology of the human meninges. , 2005, Morphologie : bulletin de l'Association des anatomistes.

[30]  S. Love,et al.  Aβ-related angiitis: primary angiitis of the central nervous system associated with cerebral amyloid angiopathy , 2005 .

[31]  A. Osborn,et al.  Giant tumefactive perivascular spaces. , 2005, AJNR. American journal of neuroradiology.

[32]  T. Mazel,et al.  Changes in extracellular space size and geometry in APP23 transgenic mice: a model of Alzheimer's disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[33]  D. Dickson,et al.  Extracellular Deposits of Aβ Produced in Cultures of Alzheimer Disease Brain Vascular Smooth Muscle Cells , 2005 .

[34]  D. Wilcock,et al.  Passive immunotherapy against Aβ in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage , 2004, Journal of Neuroinflammation.

[35]  N. Joan Abbott,et al.  Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology , 2004, Neurochemistry International.

[36]  Kurt Bürki,et al.  Aβ is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis , 2004, Nature Neuroscience.

[37]  M. Rausch,et al.  Restricted diffusion in the brain of transgenic mice with cerebral amyloidosis , 2004, The European journal of neuroscience.

[38]  R. Weller,et al.  Cerebral amyloid angiopathy plays a direct role in the pathogenesis of Alzheimer’s disease Pro-CAA position statement , 2004, Neurobiology of Aging.

[39]  D. Selkoe,et al.  Enhanced Proteolysis of β-Amyloid in APP Transgenic Mice Prevents Plaque Formation, Secondary Pathology, and Premature Death , 2003, Neuron.

[40]  F. LaFerla,et al.  Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer’s disease , 2003, Neurobiology of Aging.

[41]  J. Tolivia,et al.  Immunohistochemical study of distribution of apolipoproteins E and D in human cerebral β amyloid deposits , 2003, Experimental Neurology.

[42]  G. Plant,et al.  Cerebral Amyloid Angiopathies: A Pathologic, Biochemical, and Genetic View , 2003, Journal of neuropathology and experimental neurology.

[43]  R. Weller,et al.  Cerebral amyloid angiopathy: Pathogenesis and effects on the ageing and Alzheimer brain , 2003, Neurological research.

[44]  T. Saido,et al.  Dutch, Flemish, Italian, and Arctic mutations of APP and resistance of Aβ to physiologically relevant proteolytic degradation , 2003, The Lancet.

[45]  S. D. Preston,et al.  Capillary and arterial cerebral amyloid angiopathy in Alzheimer's disease: defining the perivascular route for the elimination of amyloid β from the human brain , 2003, Neuropathology and applied neurobiology.

[46]  C. Holmes,et al.  Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report , 2003, Nature Medicine.

[47]  T. Beach,et al.  Cortical and Leptomeningeal Cerebrovascular Amyloid and White Matter Pathology in Alzheimer’s Disease , 2003, Molecular medicine.

[48]  W. Jagust,et al.  Imaging Interactions between Alzheimer's Disease and Cerebrovascular Disease , 2002, Annals of the New York Academy of Sciences.

[49]  Zhanjiang Li,et al.  Novel glycosaminoglycan precursors as anti-amyloid agents, Part III , 2002, Journal of Molecular Neuroscience.

[50]  M. Viitanen,et al.  CADASIL: a Common Form of Hereditary Arteriopathy Causing Brain Infarcts and Dementia , 2002, Brain pathology.

[51]  H. Braak,et al.  Two Types of Sporadic Cerebral Amyloid Angiopathy , 2002, Journal of neuropathology and experimental neurology.

[52]  M. Bergsneider,et al.  Evolving concepts of cerebrospinal fluid physiology. , 2001, Neurosurgery clinics of North America.

[53]  T. Tokunaga,et al.  Overproduction of perlecan core protein in cultured cells and transgenic mice , 2001, The Journal of pathology.

[54]  D. Selkoe.  Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.

[55]  Ian G. McKeith,et al.  Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales , 2001, The Lancet.

[56]  D. Holtzman,et al.  Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. , 2000, The Journal of clinical investigation.

[57]  N. Alperin,et al.  MR-Intracranial pressure (ICP): a method to measure intracranial elastance and pressure noninvasively by means of MR imaging: baboon and human study. , 2000, Radiology.

[58]  D. Kirschner,et al.  Laminin inhibition of β‐amyloid protein (Aβ) fibrillogenesis and identification of an Aβ binding site localized to the globular domain repeats on the laminin a chain , 2000 .

[59]  R. Vos,et al.  Pathological features of cerebral cortical capillaries are doubled in Alzheimer’s disease and Parkinson’s disease , 2000, Acta Neuropathologica.

[60]  I. Tesseur,et al.  Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the London mutant of human APP in neurons , 2000, Neurobiology of Aging.

[61]  T. Beach,et al.  The Cholinergic Deficit Coincides with Aβ Deposition at the Earliest Histopathologic Stages of Alzheimer Disease , 2000, Journal of neuropathology and experimental neurology.

[62]  T. Beach,et al.  Cholinergic deafferentation of the rabbit cortex: a new animal model of Aβ deposition , 2000, Neuroscience Letters.

[63]  C. Masters,et al.  Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease , 1999, Annals of neurology.

[64]  P. Knopf,et al.  Role of the cervical lymphatics in the Th2-type hierarchy of CNS immune regulation 1 This work was supported by National Institute of Health Grant (RO1 NS33070-03) and The Brain Tumor Society. 1 , 1999, Journal of Neuroimmunology.

[65]  Zsuzsanna Nagy,et al.  Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer's disease , 1999, The Lancet.

[66]  L. Lue,et al.  Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer’s Disease , 1999 .

[67]  D. Graham,et al.  The Apolipoprotein E ∈2 Allele and the Pathological Features in Cerebral Amyloid Angiopathy-related Hemorrhage , 1999 .

[68]  M. Boulton,et al.  Contribution of extracranial lymphatics and arachnoid villi to the clearance of a CSF tracer in the rat. , 1999, American journal of physiology. Regulatory, integrative and comparative physiology.

[69]  R. Weller,et al.  Lymphocyte targeting of the brain in adoptive transfer cryolesion‐EAE , 1999, The Journal of pathology.

[70]  Y. Olsson,et al.  Amyloid angiopathy of the human brain: immunohistochemical studies using markers for components of extracellular matrix, smooth muscle actin and endothelial cells , 1998, Acta Neuropathologica.

[71]  R. Weller.  Pathology of Cerebrospinal Fluid and Interstitial Fluid of the CNS: Significance for Alzheimer Disease, Prion Disorders and Multiple Sclerosis , 1998, Journal of neuropathology and experimental neurology.

[72]  Yu-Min Kuo,et al.  Cerebral amyloid angiopathy: amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. , 1998, The American journal of pathology.

[73]  R. Weller,et al.  Role of cervical lymph nodes in autoimmune encephalomyelitis in the Lewis rat , 1997, The Journal of pathology.

[74]  James A. Mortimer,et al.  Brain Infarction and the Clinical Expression of Alzheimer Disease-Reply , 1997 .

[75]  G C Roman,et al.  Brain infarction and the clinical expression of Alzheimer disease. , 1997, JAMA.

[76]  C. Broeckhoven,et al.  Presenilin‐I polymorphism and hereditary cerebral hemorrhage with amyloidosis, Dutch type , 1997, Annals of neurology.

[77]  W. Markesbery,et al.  Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. , 1997, JAMA.

[78]  L. Thal,et al.  The apolipoprotein E epsilon 4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and Lewy body variant , 1996, Neurology.

[79]  H. Staunton,et al.  Peripheral Nerve Amyloidosis , 1996, Brain pathology.

[80]  R. Roos,et al.  Hereditary Cerebral Hemorrhage with Amyloidosis‐Dutch Type (HCHWA‐D): I ‐ A Review of Clinical, Radiologic and Genetic Aspects , 1996, Brain pathology.

[81]  Y. Ihara,et al.  Amyloid β‐proteins 1—40 and 1—42(43) in the soluble fraction of extra‐ and intracranial blood vessels , 1995 .

[82]  R O Weller,et al.  CSF drains directly from the subarachnoid space into nasal lymphatics in the rat. Anatomy, histology and immunological significance , 1993, Neuropathology and applied neurobiology.

[83]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[84]  C. Clark,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1990, Neurology.

[85]  P. Knopf,et al.  Role of cervical lymph nodes in the systemic humoral immune response to human serum albumin microinfused into rat cerebrospinal fluid , 1989, Journal of Neuroimmunology.

[86]  R. Weller,et al.  The fine anatomy of the human spinal meninges. A light and scanning electron microscopy study. , 1988, Journal of neurosurgery.

[87]  J. Pickard.  Physiology and Pathophysiology of the Cerebrospinal Fluid , 1988 .

[88]  R O Weller,et al.  The Cranial Arachnoid and Pia Mater in Man: Anatomical and Ultrastructural Observations , 1988, Neuropathology and applied neurobiology.

[89]  Anthony F. Jorm,et al.  The prevalence of dementia: A quantitative integration of the literature , 1987, Acta psychiatrica Scandinavica.

[90]  D. Perl,et al.  Neuropathology of dementia. , 1986, Neurologic clinics.

[91]  R. Aird.  A study of intrathecal, cerebrospinal fluid-to-brain exchange , 1984, Experimental Neurology.

[92]  C. Patlak,et al.  Drainage of interstitial fluid from different regions of rat brain. , 1984, The American journal of physiology.

[93]  P. Yates,et al.  ALZHEIMER'S PRESENILE DEMENTIA, SENILE DEMENTIA OF ALZHEIMER TYPE AND DOWN'S SYNDROME IN MIDDLE AGE FORM AN AGE RELATED CONTINUUM OF PATHOLOGICAL CHANGES , 1984, Neuropathology and applied neurobiology.

[94]  H Handa,et al.  Mechanical properties of human cerebral arteries. Part 1: Effects of age and vascular smooth muscle activation. , 1979, Surgical neurology.

[95]  H. Wiśniewski,et al.  Histological and ultrastructural changes with experimental hydrocephalus in adult rabbits. , 1969, Brain : a journal of neurology.

[96]  W. Scholz.  Studien zur Pathologie der Hirngefäße II , 1938 .

[97]  V. Perry,et al.  What is immune privilege (not)? , 2007, Trends in immunology.

[98]  A. Goate,et al.  Clearance of amyloid-beta by circulating lipoprotein receptors. , 2007, Nature medicine.

[99]  A. Palsdottir,et al.  Hereditary cystatin C amyloid angiopathy: genetic, clinical, and pathological aspects. , 2006, Brain pathology.

[100]  Mathias Jucker,et al.  Mechanism of cerebral beta-amyloid angiopathy: murine and cellular models. , 2006, Brain pathology.

[101]  J. Hardy.  Amyloid double trouble , 2006, Nature Genetics.

[102]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal. , 2006, Journal of Alzheimer's disease : JAD.

[103]  D. Selkoe.  Amyloid beta-peptide is produced by cultured cells during normal metabolism: a reprise. , 2006, Journal of Alzheimer's disease : JAD.

[104]  M. Frosch,et al.  The cerebral beta-amyloid angiopathies: hereditary and sporadic. , 2006, Brain pathology.

[105]  D. Dickson,et al.  Extracellular deposits of A beta produced in cultures of Alzheimer disease brain vascular smooth muscle cells. , 2005, Journal of neuropathology and experimental neurology.

[106]  David M Holtzman,et al.  Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. , 2005, Neuron.

[107]  S. Love,et al.  Abeta-related angiitis: primary angiitis of the central nervous system associated with cerebral amyloid angiopathy. , 2005, Brain : a journal of neurology.

[108]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[109]  A. Joutel,et al.  Transgenic mice expressing mutant Notch3 develop vascular alterations characteristic of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. , 2003, The American journal of pathology.

[110]  J. Tolivia,et al.  Immunohistochemical study of distribution of apolipoproteins E and D in human cerebral beta amyloid deposits. , 2003, Experimental neurology.

[111]  W. Szarek,et al.  Novel glycosaminoglycan precursors as anti-amyloid agents part II , 2002, Journal of Molecular Neuroscience.

[112]  L. Mucke,et al.  Chronic overproduction of transforming growth factor-beta1 by astrocytes promotes Alzheimer's disease-like microvascular degeneration in transgenic mice. , 2000, The American journal of pathology.

[113]  D. Kirschner,et al.  Laminin inhibition of beta-amyloid protein (Abeta) fibrillogenesis and identification of an Abeta binding site localized to the globular domain repeats on the laminin a chain. , 2000, Journal of neuroscience research.

[114]  L. Lue,et al.  Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. , 1999, The American journal of pathology.

[115]  D. Graham,et al.  The apolipoprotein E epsilon2 allele and the pathological features in cerebral amyloid angiopathy-related hemorrhage. , 1999, Journal of neuropathology and experimental neurology.

[116]  R O Weller,et al.  Cerebral amyloid angiopathy: amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. , 1998, The American journal of pathology.

[117]  J. Wegiel,et al.  Beta-amyloid formation by myocytes of leptomeningeal vessels. , 1994, Acta neuropathologica.

[118]  P. Knopf,et al.  Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view. , 1992, Immunology today.